12.5 C
New York
Wednesday, May 25, 2022

BiondVax Pharmaceuticals Ltd. (BVXV) stock surged in the Pre-market; here is why?

BiondVax Pharmaceuticals Ltd. (BVXV) stock surged in the pre-market after announcing entering into a new partnership. BVXV’s stock price is $1.58, gaining more than 15% from the previous closing price. BVXV stock closed at $1.37 at the end of the last trading session. BVXV stock volume traded in the previous trading session was around 131.14K shares. The current market cap of the company is about $13.19 million.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


BVXV: New Partnership

According to a news release, a collaborative venture between BiondVax Pharmaceuticals Ltd. (BVXV), the Max Planck Society, and the University Medical Center Göttingen to develop novel Nano-sized antibodies (NanoAbs) has been launched. If BiondVax successfully develops and commercializes NanoAbs, the company will have the sole chance to obtain an exclusive worldwide license at pre-agreed commercial terms if it does so.

BiondVax NanoAbs, for example, have greater binding strength than currently available therapies, are more stable at higher temperatures, and maybe more effective and easier to give than currently available therapeutics. Asthma, macular degeneration, and psoriatic arthritis are just a few indications where the NanoAb advantages might help the company gain a significant amount of ground. As with the previously announced COVID-19 therapeutic NanoAb, an inhaled COVID-19 therapeutic NanoAb will be developed as part of an exclusive license agreement with a pharmaceutical company.

BVXV: Next Plans

BVMV intends to accelerate development by leveraging its expertise and skills in biologic medication development and production. GMP biologic manufacturing facilities like BiondVax’s plant in Jerusalem can generate NanoAbs in large quantities using recombinant protein production. Initial pre-clinical results for the NanoAbs covered by the current agreement are expected in 2023, but development has already started. In 2022, BVMV plans to run a pre-clinical proof of concept study of COVID-19 NanoAbs inhaled. In 2023, BiondVax plans to start testing COVID-19 NanoAbs in humans.

Conclusion

BVMV has entered into a partnership that will complement its development process. Both the companies have expertise that will help them increase the possibilities of such a drug development that will have brighter chances of approval.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles